The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Atossa Therapeutics Inc shares valued at $9,887 were purchased by QUAY STEVEN C on May 21 ’25. At $0.88 per share, QUAY STEVEN C acquired 11,239 shares. The insider’s holdings grew to 13,898 shares worth approximately $11118.400000000001 following the completion of this transaction.
Also, Remmel H. Lawrence purchased 10,000 shares, netting a total of over 7,000 in proceeds. Following the buying of shares at $0.70 each, the insider now holds 10,257 shares.
As published in their initiating research note from Maxim Group on January 26, 2018, Atossa Therapeutics Inc [ATOS] has been a Buy and the price target has been revised to $2.
Analyzing ATOS Stock Performance
On last trading session,, Atossa Therapeutics Inc [NASDAQ: ATOS] plunged -0.90% to $0.80. During the last five days, there has been a drop of approximately -8.52%. Over the course of the year, Atossa Therapeutics Inc shares have dropped approximately -14.92%. Shares of the company reached a 52-week high of $1.0700 on 05/14/25 and a 52-week low of $0.5526 on 04/07/25.
Support And Resistance Levels for Atossa Therapeutics Inc (ATOS)
According to the 24-hour chart, there is a support level at 0.7919, which, if violated, would cause prices to drop to 0.7807. In the upper region, resistance lies at 0.8225. The next price resistance is at 0.8419. RSI (Relative Strength Index) is 44.09 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Atossa Therapeutics Inc (ATOS)?
In terms of Atossa Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 5 in the next 12 months, up nearly 517.28% from the previous closing price of $0.81. Analysts anticipate Atossa Therapeutics Inc stock to reach 5 by 2025, with the lowest price target being 5. In spite of this, 2 analysts ranked Atossa Therapeutics Inc stock as Buy at the end of 2025.
